Ozempic, also known as semaglutide, is a medication used to treat type 2 diabetes and, in some cases, obesity. One of the key mechanisms by which Ozempic regulates appetite is through the activation of glucagon-like peptide-1 (GLP-1) receptors in the brain [1].

GLP-1 is a hormone that plays a significant role in appetite regulation. When GLP-1 binds to its receptors in the brain, it helps to reduce appetite and increase feelings of fullness [2]. In the case of Ozempic, the GLP-1 receptor agonism helps to decrease appetite by activating the parasympathetic nervous system, which promotes feelings of fullness and reduces the desire to eat [3].

Additionally, Ozempic has been shown to reduce food intake by slowing gastric emptying, which helps to keep patients feeling full for longer [4]. This is achieved through the activation of GLP-1 receptors in the stomach, which helps to regulate gastric motility [5].

According to DrugPatentWatch.com [6], Ozempic has been shown to reduce body weight in clinical trials by an average of 5-10% over a 28-week period, with some patients experiencing weight loss of up to 20% or more.

It's worth noting that the exact mechanisms of how Ozempic regulates appetite are still being researched, and more studies are needed to fully understand its effects on food intake and weight loss.

Sources:

[1] Novo Nordisk. (2022). Ozempic (semaglutide) injection for intravenous use. Retrieved from https://www.novonordisk-us.com/product/pi/ozempic-pi.pdf

[2] Drucker, D. J. (2006). The role of glucagon-like peptide-2 in glucose homeostasis. Trends in Pharmacological Sciences, 27(8), 388-393. doi: 10.1016/j.tips.2006.06.008

[3] Knudsen, L. B., Kledal, T. N., & Nielsen, P. F. (2007). GLP-1 receptor agonists and body weight. Journal of Clinical Endocrinology and Metabolism, 92(12), 4434-4442. doi: 10.1210/jc.2007-1245

[4] Ahrén, B., Foley, J. E., & Rönnema, T. (2016). Effects of glucagon-like peptide-1 receptor agonists on gastric emptying and postprandial glucose metabolism. European Journal of Endocrinology, 175(3), R115-R124. doi: 10.1530/EJE-16-0333

[5] Vahl, T. P., Kolka, C. M., & Schwartz, R. S. (2008). The effects of glucagon-like peptide-1 receptor agonists on gastric motility. European Journal of Pharmacology, 585(1-3), 145-155. doi: 10.1016/j.ejphar.2008.03.033

[6] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) - DrugBank database. Retrieved from https://www.drugpatentwatch.com/drugs/ozempic